Wilmington Based Biotech Company Incyte Joins the S&P 500

Incyte Corp. has joined the prestigious Standard & Poor’s 500, an index of the 500 most widely held stocks on the New York Stock Exchange and Nasdaq.

“The [S&P 500] index is an important threshold for us because it has put us into a bigger arena of life sciences companies,” said Dave Gryska, Incyte’s chief financial officer.

In the past year, Incyte’s stock has skyrocketed, nearly doubling from $75 a share to today’s high of $133.

Incyte has one drug which has been approved by the U.S. Food and Drug Administration (FDA), Jakafi. Which treats a rare blood cancers. Incyte stated that it expects Jakafi to generate $1 billion in sales in 2017.

Gryska added that, “Being added to the S&P 500 listing will help Incyte attract talent to Delaware in the highly competitive life sciences market.”

Read the full article at DelawareOnline.com 

Stay Up-to-Date on Business News in Wilmington

Sign up for Our Monthly Newsletter!

Incyte logo from (PRNewsFoto/Incyte Corporation)

  • Show Comments

Your email address will not be published. Required fields are marked *

comment *

  • name *

  • email *

  • website *


You May Also Like

Ladybug Music Festival Celebrates Women in Music!

Image courtesy of Moonloop Photography. For Gayle Dillman, organizer of the annual "Ladybug Music ...

5 Reasons to Attend #MillSummit 2017

With more than 40 speakers and panelists and over 60 organizations in attendance, the ...

It’s Time to Tell the Story of Wilmington’s Rejuvenation

Mark Turner, CEO of WSFS and Rob Ward, CEO of CSC publically provided their ...

Wilmington is Recognized as a Tech Hotspot

Commercial real estate giant, CBRE analysis shows Delaware is creating highly sought-after tech jobs. ...

Copyright © 2019 WilmToday.com
Designed and Developed in Partnership with
Tapp Network - Mission-driven Marketing & Technology
Located in Wilmington, DE